key: cord-0934416-lh9tk4a4
authors: Nakhleh, Afif; Shehadeh, Naim
title: Interactions between antihyperglycemic drugs and the renin-angiotensin system: Putative roles in COVID-19. A mini-review
date: 2020-05-05
journal: Diabetes Metab Syndr
DOI: 10.1016/j.dsx.2020.04.040
sha: 11954b84ab4d75806de1f3e6a5b6204056a41a54
doc_id: 934416
cord_uid: lh9tk4a4

Abstract Background and aims: Diabetes mellitus is associated with a more severe course of coronavirus disease 2019 (COVID-19). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes angiotensin-converting enzyme II (ACE2) receptor for host cell entry. We aimed to assess the interactions between antihyperglycemic drugs and the renin-angiotensin system (RAS) and their putative roles in COVID-19. Methods A literature search was performed using Pubmed to review the interrelationships between hyperglycemia, RAS and COVID-19, and the effects of antihyperglycemic medications. Results The RAS has an essential role in glucose homeostasis and may have a role in COVID-19-induced lung injury. Some antihyperglycemic medications modulate RAS and might hypothetically alleviate the deleterious effect of angiotensin II on lung injury. Furthermore, most antihyperglycemic medications showed anti-inflammatory effects in animal models of lung injury. Conclusions Some antihyperglycemic medications might have protective effects against COVID-19-induced lung injury. Early insulin therapy seems very promising in alleviating lung injury.

of the reported COVID-19 fatalities had a history of diabetes mellitus (1) . A literature search was performed using Pubmed to review the interrelationships between hyperglycemia, reninangiotensin system (RAS) and COVID-19, and the effects of antihyperglycemic medications.

Herein, we discuss the roles of the classic and non-classic renin-angiotensin system (RAS) in lung injury and glucose homeostasis among patients with COVID-19. We also discuss the putative roles of glucose-lowering medications in type 2 diabetic patients with COVID-19 and introduce the current evidence for their use in hospitalized patients.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses angiotensinconverting enzyme II (ACE2) receptor to enter the host cell and the serine protease TMPRSS2 for virus spike protein priming (2) . The binding of SARS-CoV-1 Spike protein to ACE2 activates disintegrin and metalloprotease-17 (ADAM17) and induces ACE2 shedding via a process tightly coupled with TNF-α production (3) . Down-regulation of ACE2 cell surface expression in lung tissue is associated with a severe clinical outcome in cases of SARS-CoV-1 infection (4) . Considering that SARS-CoV-1 and SARS-CoV-2 share >70% sequence in the Spike protein (5), SARS-CoV-2 is likely to downregulate the ACE2 expression. Recently, Monteil V et al. showed that human recombinant soluble ACE2 significantly blocks SARS-CoV-2 infections, providing a rationale that soluble ACE2 might not only protect from lung injury but also block the SARS-CoV-2 from entering target cells (6) .

ACE2 is expressed in the lung, kidney, pancreas and other tissues, and degrades angiotensin II to angiotensin-(1-7) (7). The ACE2 receptor protects against lung injury by modulating of the RAS and decreasing angiotensin II levels (8) . Moreover, activation of the angiotensin (1-7)/ACE2 axis inhibits reactive oxygen species production, downregulates proinflammatory cytokine secretion, and has immunomodulatory tissue-protective features (9) . From a physiologic standpoint, while increased baseline ACE2 expression could potentially increase SARS-CoV-2 infectivity, upregulation of ACE2 expression and ACE2 replacement in the acute respiratory distress syndrome phase (ARDS) phase may turn out to be beneficial.

Accumulating evidence supports the protective roles of ACE2 in diabetes. ACE2 might play several roles in glucose homeostasis: 1) ACE2 deficiency leads to altered glucose metabolism; ACE2-knockout mice showed a βcell defect associated with a decrease in insulin secretion in a manner that is not dependent on angiotensin II but may reflect the collectrin-like action of ACE2 (10). In mice, ACE2 overexpression in the pancreas significantly improved glucose tolerance, enhanced islet function, and increased β-cell proliferation and insulin content (11) .

2) Loss of ACE2 increases insulin resistance in the high-calorie diet fed mice, by reduction of GLUT4, and administration of angiotensin-(1-7) improved insulin tolerance, suggesting a significant role of angiotensin-(1-7) in glucose homeostasis (12) .

3) Hyperglycemia stimulates tissue RAS and vice versa; that is, increased activity of angiotensin II signaling pathways contribute to the development of diabetes and its complications (13, 14) . ACE2 is thought to act as a compensatory mechanism for hyperglycemia-induced RAS activation. Loss of ACE2 in mice disrupts the balance of the RAS in a diabetic state and leads to an angiotensin II/AT1 receptor-dependent systolic dysfunction and impaired vascular function (15) .

ADAM17 is involved in the shedding of transmembrane ACE2 to release the catalytically active ectodomain into the circulation (16) . ADAM17-mediated ectodomain shedding might compromise the RAS compensatory axis by impairing ACE2 enzymatic activity or its ability to process angiotensin II on the cell surface (16) . In mice, hyperglycemia increases ADAM17 activity and renal ACE2 shedding into the urine (17) . This urinary ACE2 excretion correlated positively with the progression of diabetic renal injury, probably resembling an unopposed angiotensin II effect. In humans, urinary ACE2 levels are significantly higher in insulin-resistant subjects and type 2 diabetes mellitus than in controls with normal glucose tolerance (18) . In addition, urinary ACE2 appears to be positively associated with inflammatory cytokines, resembling increased ACE2 shedding (18) .

4) The localization of ACE2 expression in the endocrine part of the pancreas suggests that SARS coronavirus enters islets using ACE2 as its receptor and damages islets causing acute diabetes. In fact, Yang J et al. reported that 50% of SARS patients who had no previous history of diabetes or steroid treatment, have been diagnosed with diabetes during hospitalization, and only 10% had diabetes after 3 years of follow-up (19) .

It can be hypothesized that SARS-CoV-2-mediated downregulation of ACE2 expression in the pancreas and peripheral tissues may decrease insulin secretion, increase insulin resistance and, induce hyperglycemia-induced RAS activation. On the other hand, ACE2 expression in the pancreas might facilitate SARS-CoV-2 invasion and direct β-cell damage.

ADAM17 activation by SARS-CoV-2 might also increase the risk of hyperglycemia. In mice, accumulating evidence suggests that increased ADAM17 activity results in increased insulin resistance and hyperglycemia (20) . ADAM17 plays a potential role in inflammation, as it can cleave and thereby activate a variety of cytokines and cytokine receptors including tumor necrosis factor α (TNFα) and the interleukin-6 receptor (IL-6R) (21) . Increased inflammation might also contribute to the development of islet β-cell failure (22) . Accumulating evidence suggests that patients with severe COVID-19 and ARDS might have a cytokine storm syndrome, including high levels of IL-6 and TNFα (23) . Meanwhile, RAS activation can propagate acute lung injury (24) .

Hyperglycemia is commonly observed during acute and critical illness. Early administration of insulin in acute illness is associated with better outcomes and lower mortality rates (25) .

Insulin therapy in diabetic patients with COVID-19 disease that warrant hospital care, might be associated with better outcomes, and here are the explanations: 1) Insulin exerts immunomodulatory effects independent of glycemic control. Several studies suggest a potential benefit of insulin therapy in different animal models of acute lung injury and ARDS. Insulin inhibits synthesis of pro-inflammatory factors including TNFα and IL-6 and attenuates oxidative stress seen in acute lung injury (26, 27) .

2) Treating hyperglycemia with insulin might restore ACE2 and ADAM17 expression and the RAS balance, as was shown in mice. In the Akita mouse model of type 1 diabetes, insulin treatment normalized hyperglycemia, decreased urinary ACE2 excretion, restored renal ACE2 and ADAM17 expression to physiological levels, and normalized the rate of shedding (28) . A recent study has demonstrated a marked serum and pulmonary alterations in the ACE activity of non-obese diabetic (NOD) mice. In the lung of NOD mice, ACE activity was increased, and the ACE2/ACE activity ratio was decreased, as compared to control mice. Interestingly, insulin significantly increased ACE2/ACE activity ratio in the mice lung, and restored ACE and ACE2, and ACE2/ACE ratio activities in serum samples (29) . Therefore, it can be hypothesized that by restoring ACE2 expression to physiological levels on the cell surface and decreasing angiotensin II levels, insulin therapy might prevent the rapid propagation toward cytokine storm and lung injury in COVID-19.

3) Early insulin therapy reduces the risk of developing diabetic ketoacidosis or hyperglycemic hyperosmolar states, taking into account that some diabetic patients with COVID-19 may deteriorate rapidly to acute lung injury and ARDS.

Other antihyperglycemic medications (Table 1) 2) Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists attenuated lipopolysaccharide (LPS)-induced lung injury in murine models (32) . Of note, in type 2 diabetic mice, the insulin sensitizer rosiglitazone normalized hyperglycemia, attenuated renal injury and decreased urinary ACE2 excretion and renal ADAM17 protein expression, but, unlike insulin, did not affect renal ACE2 expression (33) . On the other hand, pioglitazone upregulated ACE2 protein expression in liver, adipose tissue, and skeletal muscle in rats with high-fat diet-induced nonalcoholic steatohepatitis (34) . An elevated ACE2 expression in insulin-sensitive tissues can attenuate the angiotensin II-induced insulin resistance. Pioglitazone effect on ACE2 expression in the lung is unknown. However, taking into consideration the risk of fluid retention, it is advisable to withhold PPAR-γ agonists in acutely ill patients. (39) . Interestingly, the GLP-1 agonist, liraglutide, provoked an increase in ACE2 expression in the lungs of both diabetic and control rats, and in the circulating angiotensin (1-7) in diabetic animals (40) . Based on these findings, it might be proposed that GLP-1 agonist therapy might exert protective effects against SARS-CoV-2 induced lung injury. 5) There is some emerging evidence suggesting anti-inflammatory effect of sodium glucose co-transporter 2 inhibitors (SGLT2) inhibitors (41) . However, recently published treatment recommendations advise to withhold these agents during COVID-19 illness due to the increased risk of dehydration and development of diabetic ketoacidosis (DKA) (42) .

Anyhow, a prospective phase III clinical study is ongoing to assess the potential effect of dapagliflozin in reducing the risk of serious complications and organ failure in hospitalized patients with COVID-19 illness (Clinicaltrials.gov NCT04350593).

(43).

6) The sulfonylurea, glibenclamide can alleviate acute lung injury by inhibiting the nucleotide-binding oligomerization domain (NOD)-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome signaling pathway (44) . Glibenclamide downregulates proinflammatory cytokines and reactive oxygen species and suppresses migration of inflammatory cells (45) . However, the use of sulfonylureas in the inpatient setting is discouraged because of the potential risk of hypoglycemia (46) .

In summary, the current evidence reveals considerable interrelationships between hyperglycemia and coronavirus-induced lung injury. Insulin therapy seems very promising in alleviating lung injury. Given the wide clinical spectrum of COVID-19 and the fact that patients needing hospital care may deteriorate rapidly, it is reasonable to consider the early introduction of insulin upon admission to the hospital. The suggested target glucose range is 140-180 mg/dL (7.8-10.0 mmol/L) in most cases (47) . Although considerable evidence supports the use of incretin-based therapies in critically ill patients with hyperglycemia, more prospective studies comparing these agents with insulin are required to establish their efficacy and safety (48, 49) . Other antihyperglycemic agents lack safety data concerning their use in hospitalized patients with moderate or severe COVID-19 pneumonia. Future studies should be carried out to elucidate the interface between diabetes and COVID-19 and unveil glycemic and extra-glycemic effects of glucose-lowering medications in this disease.

Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in China

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. cell

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Classic and Nonclassic Renin-Angiotensin Systems in the Critically Ill

ACE2 deficiency shifts energy metabolism towards glucose utilization

Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice

Loss of ACE2 exaggerates high-calorie diet-induced insulin resistance by reduction of GLUT4 in mice

The sweeter side of ACE2: Physiological evidence for a role in diabetes

High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes

Loss of angiotensinconverting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: A critical role of the angiotensin II/AT1 receptor axis

Functional and molecular evidence for expression of the renin angiotensin system and ADAM17-mediated ACE2 shedding in COS7 cells

Characterization of angiotensin-converting enzyme 2 ectodomain shedding from mouse proximal tubular cells

High urinary ACE2 concentrations are associated with severity of glucose intolerance and microalbuminuria

Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes

Increased tumor necrosis factor α-converting enzyme activity induces insulin resistance and hepatosteatosis in mice

The metalloprotease ADAM17 in inflammation and cancer

Inflammatory mediators and islet β-cell failure: A link between type 1 and type 2 diabetes

COVID-19: immunopathology and its implications for therapy

Recombinant human ACE2: Acing out angiotensin II in ARDS therapy

Early versus late intravenous insulin administration in critically ill patients

Diabetes, insulin, and development of acute lung injury

Critical Care Medicine. Lippincott Williams and Wilkins

Insulin attenuates endotoxin-induced acute lung injury in conscious rats

Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice

Characterization of ACE and ACE2 expression within different organs of the NOD mouse

Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury

Metformin-associated lactic acidosis: Current perspectives on causes and risk

Pioglitazone attenuates endotoxin-induced acute lung injury by reducing neutrophil recruitment

Rosiglitazone Treatment of Type 2 Diabetic db/db Mice Attenuates Urinary Albumin and Angiotensin Converting Enzyme 2 Excretion

Pioglitazone Upregulates Angiotensin Converting Enzyme 2 Expression in Insulin-Sensitive Tissues in Rats with High-Fat Diet-Induced Nonalcoholic Steatohepatitis

DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice

The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

Effects of DPP4 Inhibition on COVID-19 -Full Text View -ClinicalTrials.gov

GLP-1 Analogue Liraglutide Enhances SP-A Expression in LPS-Induced Acute Lung Injury through the TTF-1

Signaling Pathway

Activation of the GLP-1 Receptor by Liraglutide Increases ACE2

Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes Rats

Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidativeinflammatory-apoptotic pathway

Practical recommendations for the management of diabetes in patients with COVID-19

Dapagliflozin in Respiratory Failure in Patients With COVID-19 -Full Text View -ClinicalTrials.gov . Available from

Glibenclamide alleviates inflammation in oleic acid model of acute lung injury through NLRP3 inflammasome signaling pathway

A Protective Role of Glibenclamide in Inflammation-Associated Injury

Pharmacotherapy for hyperglycemia in noncritically ill hospitalized patients

Association AD. 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2020

Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios

Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? the time has come for GLP-1 receptor agonists! Diabetes Care